For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Idun Pharmaceuticals, Inc.

USPTO Granted Patents = 33

CIPO Patents = 1

Forward Citations = 297

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Kevin J Tomaselli (15 out of 22 patents)

Steven D Linton (11 out of 11 patents)

Robert J Ternansky (10 out of 35 patents)

4. Lawrence C Fritz (10 out of 11 patents)

5. Donald Karanewsky (9 out of 62 patents)

6. Xu Bai (8 out of 10 patents)

7. Donald S Karanewsky (7 out of 61 patents)

8. Robert Craig Armstrong (6 out of 18 patents)

9. Patricia L Gladstone (4 out of 7 patents)

10. Tilman Oltersdorf (3 out of 7 patents)

11. Teresa Fernandes-Alnemri (3 out of 14 patents)

12. Emad S Alnemri (3 out of 34 patents)

13. Gerald Litwack (3 out of 21 patents)

14. William A Horne (3 out of 3 patents)

15. Jose-Luis Diaz (3 out of 3 patents)

33 patents: Sort by Forward Citations

1. 7183260 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2007-02-27),

2. 7157430 - (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases (2007-01-02),

3. 7053056 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2006-05-30),

4. 6969703 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2005-11-29),

5. 6897296 - Antibody that specifically binds an Mch5 polypeptide (2005-05-24),

6. 6824991 - Human bad polypeptides, encoding nucleic acids and methods of use (2004-11-30),

7. 6790989 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2004-09-14),

8. 6762045 - Membrane derived caspase-3, compositions comprising the same and methods of use therefor (2004-07-13),

9. 6693096 - Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2004-02-17),

10. 6610683 - Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-08-26),

11. 6544951 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2003-04-08),

12. 6531467 - Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-11),

13. 6528506 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-04),

14. 6525024 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2003-02-25),

15. 6518032 - Rapid methods for identifying modifiers of cellular apoptosis activity (2003-02-11),

Idun Pharmaceuticals, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases. With cutting-edge research and a commitment to improving patient outcomes, we strive to bring transformative treatments to those in need. Our team of experienced scientists and dedicated professionals work tirelessly to advance our pipeline of drug candidates, with a strong emphasis on precision medicine and personalized therapies. Visit our website to learn more about our mission, current projects, and how we are making a difference in the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

33 Patents

#184 in San Diego, CA

#2,381 in California

#9,947 in US

#19,554 in the World

San Diego, CA, United States of America

Idun Pharmaceuticals, Inc.

Forward Citations = 297

27 inventors:

Kevin J Tomaselli (15 out of 22 patents)

Steven D Linton (11 out of 11 patents)

Robert J Ternansky (10 out of 35 patents)

4. Lawrence C Fritz (10 out of 11 patents)

5. Donald Karanewsky (9 out of 62 patents)

Please report any incorrect information to support@idiyas.com

Loading…